September 23, 2024
感染症を専門とする公衆衛生専門家と SCARDA 研究者との合同ワクチン国際シンポジウム

Hiroshi Kiyono, D.D.S., Ph.D.
Distinguished Professor, Future Medicine Education and Research Organization,Director, Synergy Institute for Futuristic Mucosal Vaccine Research andDevelopment (cSIMVa), Chiba University (CU), Chiba, Japan
Co-Director/Adjunct Professor, CU-UCSD Center for Mucosal Immunology, Allergyand Vaccines (cMAV), UC San Diego School of Medicine, San Diego, CA, USA
Dr. Kiyono’s background as a dentist combined with his Ph.D in Experimental Pathology andextensive research experience in the field of Mucosal Immunology makes him exceptionally wellqualified to discuss the current and future directions of mucosal immunology and mucosal
vaccine development. To reflect his scientific contribution, he has published 609 original papers
and 144 peer refereed review articles.
2022-Present Director, cSIMVa, Chiba University2022-Present Distinguished Professor, Future Medicine Education and Research Organization
and Department of Human Mucosal Vaccinology, Chiba University
2018-Present Adjunct Professor, Division of Gastroenterology, Department of Medicine andCU-UCSD cMAV, University of California, San Diego
2018-2022
IMSUT Distinguished Professor, Department of Mucosal Immunology, IMSUTDistinguished Professor Unit, The Institute of Medical Science, The University ofTokyo (IMSUT)
2018-Present Professor Emeritus, The University of Tokyo
2011-2019
Director, International Research & Development Center for Mucosal Vaccines,IMSUT
2011-2015
Dean, IMSUT
2002-2018
Professor and Director, Division of Mucosal Immunology, IMSUT
1994-2003
Professor and Chairman, Department of Mucosal Immunology, ResearchInstitute for Microbial Diseases, Osaka University
1991-2003
Professor, Departments of Oral Biology and Microbiology, UAB
1989-1990
Associate Professor, Departments of Oral Biology and Microbiology, UAB
1986-1987
Visiting Senior Scientist, Max-Planck Institute for Biology①Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y. and Kiyono, H. 2023. Nasal
vaccines: solutions for respiratory infectious diseases. Trends. Mol. Med. 29: 124-140.
② Kamioka, M., Goto, Y., Nakamura, K., Yokoi, Y., Sugimoto, R., Ohira, S., Kurashima, Y.,Umemoto, S., Sato, S., Kunisawa, J., Takahashi, Y., Domino, S.E., Renauld, J-C., Nakae, S.,
Iwakura, Y., Peter B.E., Ayabe, T. and Kiyono, H. 2022. Intestinal commensal microbiota andcytokines regulate Fut2+ Paneth cells for gut defense. Proc. Natl. Acad. Sci. USA. 119:e2115230119.
③Yuki, Y., Nojima, M., Hosono, O., Tanaka, H., Kimura, Y., Satoh, T., Imoto, S., Uematsu, S.,
Kurokawa, S., Kashima, K., Mejima, M., Nakahashi-Ouchida, R., Uchida, Y., Marui, T., Yoshikawa,N., Nagamura, F., Fujihashi, K. and Kiyono, H. 2021. Oral MucoRice-CTB vaccine for safety andmicrobiota-dependent immunogenicity in humans: a phase 1 randomized trial. Lancet Microbe.
2:e429-e440.
④Kurashima, Y., Kigoshi, T., Murasaki, S., Arai, F., Shimada, K., Seki, N., Kim, Y.G., Hase, K.,Ohno, H., Kawano, K., Ashida, H., Suzuki, T., Morimoto, M., Saito, Y., Sasou, A., Goda, Y., Yuki,Y., Inagaki, Y., Iijima, H., Suda, W., Hattori, M. and Kiyono, H. 2021. Pancreatic Glycoprotein 2
is a first line of defense for mucosal protection in intestinal inflammation. Nat. Commun.
12:1067.
⑤Goto, Y., Obata, T., Kunisawa, J., Sato, S., Ivanov, I., Lamichhane, A., Takeyama, N., Kamioka,M., Sakamoto, M., Matsuki, T., Setoyama, H., Imaoka, A., Uematsu, S., Akira, S., Domino, S.,Kulig, P., Becher, B., Renauld, J-C., Sasakawa, C., Umesaki, Y., Benno, Y. and Kiyono, H. 2014.
Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 345: 1254009.
(Article)